Amendments to the Claims

Please amend Claims 1 and 15. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently amended) A method of classifying a lymphoma sample according to predicted treatment outcome comprising determining a gene expression profile of gene expression products from at least two ~~or more~~ informative genes ~~selected from the group consisting of the genes in Figures 1, 2A, and 2B excluding the p16 gene,~~ having GenBank Accession Nos. L20971 and M18255, wherein the gene expression products are isolated from one or more cells in the sample, and wherein the gene expression profile of the two informative genes having GenBank Accession Nos. L20971 and M18255 is correlated with a treatment outcome, thereby classifying the sample with respect to treatment outcome.

2. (Original) A method according to Claim 1, wherein the lymphoma sample is a diffuse large cell lymphoma sample.

3. (Previously presented) A method according to Claim 1, wherein the gene expression products are mRNA.

4. (Previously presented) A method according to Claim 3, wherein the gene expression profile is determined using hybridization probes specific to the two or more informative genes.

5. (Original) A method according to Claim 3, wherein the gene expression profile is determined using oligonucleotide microarrays.

6-7. (Canceled)

9900356_1.DOC

8.   (Original) A method according to Claim 1, wherein the predicted treatment outcome is survival after treatment.

9-14.   (Canceled)

15.   (Currently amended) A method of classifying a sample according to lymphoma type comprising determining a gene expression profile of gene expression products from at least two ~~or more~~ informative genes ~~selected from the group consisting of the genes in Figures 3A, 3B, 4A, and 4B excluding thecathepsin B gene, the cyclin B1 gene, and the CD3 epsilon gene,~~ having GenBank Accession Nos. L17131 and U29680, wherein the gene expression ~~product is~~ products are isolated from one or more cells in the sample,
wherein the gene expression profile of the two informative genes having GenBank Accession Nos. L17131 and U29680 is correlated with a lymphoma type, thereby classifying the sample with respect to lymphoma type.

16.   (Original) A method according to Claim 15, wherein the lymphoma type is diffuse large cell lymphoma.

17.   (Original) A method according to Claim 15, wherein the lymphoma type is follicular lymphoma.

18.   (Previously presented) A method according to Claim 15, wherein the gene expression products are mRNA.

19.   (Previously presented) A method according to Claim 18, wherein the gene expression profile is determined using hybridization probes specific to the two or more informative genes.

20.   (Original) A method according to Claim 18, wherein the gene expression profile is determined using oligonucleotide microarrays.

21-36. (Canceled)

37.   (Previously presented) The method of Claim 1, wherein the gene expression products are isolated from at least five informative genes from one or more cells in said sample and wherein a gene expression profile of said at least five informative genes is determined.

38.   (Previously presented) The method of Claim 1, wherein the gene expression products are isolated from at least ten informative genes from one or more cells in said sample and wherein a gene expression profile of said at least ten informative genes is determined.

39.   (Previously presented) The method of Claim 15, wherein the gene expression products are isolated from at least five informative genes from one or more cells in said sample and wherein a gene expression profile of said at least five informative genes is determined.

40.   (Previously presented) The method of Claim 15, wherein the gene expression products are isolated from at least ten informative genes from one or more cells in said sample and wherein a gene expression profile of said at least ten informative genes is determined.